Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 5,545 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total value of $170,065.15. Following the completion of the sale, the insider owned 20,110 shares in the company, valued at approximately $616,773.70. The trade was a 21.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The stock was sold at an average price of $32.03, for a total transaction of $152,687.01.
• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total value of $208,391.04.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $29.81 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $19.55 and a 1 year high of $40.22. The company has a market capitalization of $1.92 billion, a PE ratio of -8.93 and a beta of 1.23. The company has a fifty day moving average of $31.17 and a two-hundred day moving average of $32.20.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The firm had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. On average, research analysts expect that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in STOK. BlackRock Inc. purchased a new stake in shares of Stoke Therapeutics in the second quarter valued at about $192,307,000. Jupiter Topco LLC acquired a new position in shares of Stoke Therapeutics during the 2nd quarter worth approximately $59,358,000. California State Teachers Retirement System lifted its stake in Stoke Therapeutics by 3,078.9% in the 2nd quarter. California State Teachers Retirement System now owns 1,640,515 shares of the company’s stock valued at $50,138,000 after buying an additional 1,588,909 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Stoke Therapeutics by 333.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock valued at $46,031,000 after buying an additional 1,116,452 shares during the last quarter. Finally, State Street Corp grew its holdings in Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after buying an additional 1,072,176 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently weighed in on STOK shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 11th. The Goldman Sachs Group initiated coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They set an “overweight” rating and a $40.00 target price for the company. Finally, Canaccord Genuity Group lowered their price target on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $44.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.